Serum HE4 and polymorphisms in MMP9 and MMP13 associated with survival outcome in patients with endometrial carcinoma: a retrospective cohort study and nomogram development | Synapse
April 28, 2026Future Science OA0 citationsOpen Access
Serum HE4 and polymorphisms in MMP9 and MMP13 associated with survival outcome in patients with endometrial carcinoma: a retrospective cohort study and nomogram development
To investigate the association of serum HE4 and polymorphisms in MMP9 and MMP13 with survival outcomes in endometrial carcinoma patients.
Conducted a retrospective cohort study on patients with endometrial carcinoma.
Analyzed serum HE4 levels and genetic polymorphisms in MMP9 and MMP13.
Developed a nomogram for predicting survival outcomes based on these biomarkers.
HE4 levels significantly correlated with three-year survival outcomes (p<0.05).
MMP9 R279Q and MMP13 rs2252070 polymorphisms associated with improved progression-free survival (PFS).
Nomogram demonstrated good predictive capability for three-year survival outcomes.
Abstract
HE4 is a valuable biomarker associated with three-year survival in EC. The phenotypes of MMP9 R279Q and MMP13 rs2252070 may also be associated with three-year PFS.